Related Experiment Video
Updated: Jun 23, 2026
06:23
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
Abeta aggregation and possible implications in Alzheimer's disease pathogenesis
Prashant R Bharadwaj1, Ashok K Dubey, Colin L Masters
1CSIRO Molecular and Health Technologies and P-Health Flagship, 343 Royal Parade, Parkville, Victoria, Australia.
Journal of Cellular and Molecular Medicine
|April 21, 2009
Summary
Alzheimer's disease (AD) involves amyloid beta protein (Abeta) plaque buildup. Understanding factors affecting Abeta aggregation and toxicity is crucial for developing new AD prevention strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Amyloid beta protein (Abeta) is a key component of brain plaques in Alzheimer's disease (AD).
- Cognitive decline in AD correlates with elevated Abeta levels.
- Sporadic AD is linked to impaired Abeta clearance, unlike familial AD's increased production.
Purpose of the Study:
- To review factors influencing Abeta aggregation and toxicity.
- To characterize factors involved in Abeta aggregation and accumulation in sporadic AD.
- To explore potential strategies for AD prevention through understanding Abeta oligomerization.
Main Methods:
- Review of studies on recombinant-derived or chemically synthesized Abeta.
- In vitro cell culture studies, including neuronal, mammalian, and non-mammalian cells.
- Examination of Abeta aggregation and toxicity mechanisms.
Main Results:
- Abeta aggregation and deposition are essential events in AD pathogenesis.
- Various factors influence Abeta aggregation and its toxicity.
- Cell cultures demonstrate susceptibility to Abeta toxicity.
Conclusions:
- Understanding Abeta oligomerization is vital for developing effective AD prevention strategies.
- Further characterization of factors affecting Abeta aggregation is needed for sporadic AD.
- In vitro studies provide insights into Abeta's role in AD.
More Related Videos
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...